These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29530550)

  • 21. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.
    Rausch M; Hiestand P; Foster CA; Baumann DR; Cannet C; Rudin M
    J Magn Reson Imaging; 2004 Jul; 20(1):16-24. PubMed ID: 15221804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis.
    Linker RA; Lee DH; Demir S; Wiese S; Kruse N; Siglienti I; Gerhardt E; Neumann H; Sendtner M; Lühder F; Gold R
    Brain; 2010 Aug; 133(Pt 8):2248-63. PubMed ID: 20826430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
    Komnig D; Dagli TC; Habib P; Zeyen T; Schulz JB; Falkenburger BH
    J Neurochem; 2018 Dec; 147(5):678-691. PubMed ID: 30152864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.
    Rothhammer V; Kenison JE; Tjon E; Takenaka MC; de Lima KA; Borucki DM; Chao CC; Wilz A; Blain M; Healy L; Antel J; Quintana FJ
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2012-2017. PubMed ID: 28167760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate.
    Aharoni R; Sasson E; Blumenfeld-Katzir T; Eilam R; Sela M; Assaf Y; Arnon R
    Exp Neurol; 2013 Feb; 240():130-44. PubMed ID: 23153580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing IL-17 protects the optic nerve from autoimmune pathology and prevents retinal nerve fiber layer atrophy during experimental autoimmune encephalomyelitis.
    Knier B; Rothhammer V; Heink S; Puk O; Graw J; Hemmer B; Korn T
    J Autoimmun; 2015 Jan; 56():34-44. PubMed ID: 25282335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physical Exercise Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Peripheral Immune Response and Blood-Brain Barrier Disruption.
    Souza PS; Gonçalves ED; Pedroso GS; Farias HR; Junqueira SC; Marcon R; Tuon T; Cola M; Silveira PCL; Santos AR; Calixto JB; Souza CT; de Pinho RA; Dutra RC
    Mol Neurobiol; 2017 Aug; 54(6):4723-4737. PubMed ID: 27447807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of brain-derived neurotrophic factor (BDNF) in MP4-induced autoimmune encephalomyelitis.
    Javeri S; Rodi M; Tary-Lehmann M; Lehmann PV; Addicks K; Kuerten S
    Clin Immunol; 2010 Nov; 137(2):181-9. PubMed ID: 20797911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner.
    Patnaik A; Spiombi E; Frasca A; Landsberger N; Zagrebelsky M; Korte M
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair.
    Zhang Y; Li X; Ciric B; Ma CG; Gran B; Rostami A; Zhang GX
    Mol Ther; 2017 Feb; 25(2):401-415. PubMed ID: 28153091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-IL-17A treatment reduces clinical score and VCAM-1 expression detected by in vivo magnetic resonance imaging in chronic relapsing EAE ABH mice.
    Mardiguian S; Serres S; Ladds E; Campbell SJ; Wilainam P; McFadyen C; McAteer M; Choudhury RP; Smith P; Saunders F; Watt G; Sibson NR; Anthony DC
    Am J Pathol; 2013 Jun; 182(6):2071-81. PubMed ID: 23602647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.
    Bail K; Notz Q; Rovituso DM; Schampel A; Wunsch M; Koeniger T; Schropp V; Bharti R; Scholz CJ; Foerstner KU; Kleinschnitz C; Kuerten S
    J Neuroinflammation; 2017 Jul; 14(1):148. PubMed ID: 28738885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis.
    Iglesias-Bregna D; Hanak S; Ji Z; Petty M; Liu L; Zhang D; McMonagle-Strucko K
    J Pharmacol Exp Ther; 2013 Oct; 347(1):203-11. PubMed ID: 23892570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cortical atrophy in experimental autoimmune encephalomyelitis: in vivo imaging.
    MacKenzie-Graham A; Rinek GA; Avedisian A; Gold SM; Frew AJ; Aguilar C; Lin DR; Umeda E; Voskuhl RR; Alger JR
    Neuroimage; 2012 Mar; 60(1):95-104. PubMed ID: 22182769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purkinje cell loss in experimental autoimmune encephalomyelitis.
    MacKenzie-Graham A; Tiwari-Woodruff SK; Sharma G; Aguilar C; Vo KT; Strickland LV; Morales L; Fubara B; Martin M; Jacobs RE; Johnson GA; Toga AW; Voskuhl RR
    Neuroimage; 2009 Dec; 48(4):637-51. PubMed ID: 19589388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain MRI of nasal MOG therapeutic effect in relapsing-progressive EAE.
    Levy Barazany H; Barazany D; Puckett L; Blanga-Kanfi S; Borenstein-Auerbach N; Yang K; Peron JP; Weiner HL; Frenkel D
    Exp Neurol; 2014 May; 255():63-70. PubMed ID: 24552689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
    Oommen VV; Tauhid S; Healy BC; Chua AS; Malik MT; Diaz-Cruz C; Dupuy SL; Weiner HL; Chitnis T; Bakshi R
    J Neuroimaging; 2016; 26(2):184-7. PubMed ID: 26445919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.